Arlington Partners’s Cytokinetics CYTK Stock Holding History

Arlington Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23	Closed	–	–	394
2020 Q4	$0	Buy	+23	New	+$420	﹤0.01%	228

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Arlington Partners's CYTK Position: Q1 2021 in Review

Arlington Partners sold out of Cytokinetics (CYTK) in Q1 2021, closing a stake of 23 shares.

Arlington Partners first reported a position in CYTK in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 192 funds tracked by Wall St. Rank hold CYTK as of Q1 2021.

Arlington Partners reported no remaining Cytokinetics position as of Q1 2021 after selling out during the quarter.
Arlington Partners sold 23 Cytokinetics shares in Q1 2021.
Arlington Partners first reported a position in Cytokinetics in Q4 2020 and held it in 1 quarter.
Arlington Partners's Cytokinetics position peaked at $0 in Q4 2020.
192 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2021.

Based on Arlington Partners's 13F filing for Q1 2021, filed 19 Apr 2021.